Relay Therapeutics gave Third Rock Ventures and its other investors news they could appreciate on Friday, announcing interim phase I data that support the potential of its FGFR2 inhibitor, RLY-4008, to treat intrahepatic cholangiocarcinoma, a form of liver cancer that develops in the cells of the bile ducts.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,